Search

Displaying results 1951 - 1960 of 4600 in total
  1. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  2. Drug

    Aliskiren

    go.drugbank.com/drugs/DB09026
    ApprovedInvestigational

    [A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.

  3. Drug

    Certolizumab pegol

    go.drugbank.com/drugs/DB08904
    ApprovedInvestigational

    [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]

  4. Drug

    Coenzyme M

    go.drugbank.com/drugs/DB09110
    ApprovedInvestigational

    Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]

  5. Drug

    Propylene glycol

    go.drugbank.com/drugs/DB01839
    ApprovedInvestigational

    A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.

    Mixtures: SYSTANE ULTRA (UD) (LUBRICANT EYE DROPS), SK Lubricant Eye Drops
  6. Drug

    Hydroxyethyl Starch

    go.drugbank.com/drugs/DB09106
    ApprovedInvestigational

    Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. HES is a general term and can be sub-classified acc...

  7. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    It was superseded by [pioglitazone] and [rosiglitazone].

  8. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  9. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264254] By binding to IL-31RA, nemolizumab blocks the IL-31 signalling cascades that lead to inflammation. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]

  10. Drug

    Isosorbide dinitrate

    go.drugbank.com/drugs/DB00883
    ApprovedInvestigational

    Its actions are similar to nitroglycerin but with a slower onset of action.